In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2+ breast cancer
Sakr, Rita A.
Hanker, Ariella B.
King, Tari A.
Reis-Filho, Jorge S.
Arteaga, Carlos L.
Park, So Yeon
MetadataShow full item record
CitationJaniszewska, M., L. Liu, V. Almendro, Y. Kuang, C. Paweletz, R. A. Sakr, B. Weigelt, et al. 2015. “In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2+ breast cancer.” Nature genetics 47 (10): 1212-1219. doi:10.1038/ng.3391. http://dx.doi.org/10.1038/ng.3391.
AbstractDetection of minor genetically distinct subpopulations within tumors is a key challenge in cancer genomics. Here we report STAR-FISH (Specific-To-Allele PCR – FISH), a novel method for the combined detection of single nucleotide and copy number alterations in single cells in intact archived tissues. Using this method, we assessed the clinical impact of changes in the frequency and topology of PIK3CA mutation and HER2/ERBB2 amplification within HER2+ breast cancer during neoadjuvant therapy. We found that the two genetic events are not always present within the same cell. Chemotherapy selects for PIK3CA mutant cells, a minor subpopulation in nearly all treatment-naïve samples, and modulates genetic diversity within tumors. Treatment-associated changes in spatial distribution of cellular genetic diversity correlated with poor long-term outcome following adjuvant trastuzumab therapy. Our findings support the use of in situ single-cell based methods in cancer genomics and imply that chemotherapy before HER2-targeted therapy may promote treatment resistance.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26860200